Novartis: Ovarian cancer drug disappoints in trial

May 27, 2010

(AP) -- Swiss drug maker Novartis AG said Thursday it won't ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.

The drug, patupilone, failed to show improvements over existing drugs in 829 patients with advanced .

"Novartis does not plan to proceed with regulatory filings based on these data," the Basel-based company said.

Patupilone also is being tested for treatment of certain types of colorectal, lung and .

Shares in Novartis closed 1.6 percent higher at 51.85 Swiss francs ($45.01) in line with a general lift on the Zurich exchange.

Explore further: Medical charity accuses US of pushing India to ease patent rules

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Novartis says on track to deliver US vaccine order

Oct 29, 2009

(AP) -- Swiss drugmaker Novartis AG said Thursday it is on track to meet its U.S. government order for swine flu vaccine, seeking to calm fears in recent weeks that shipments and vaccination programs may be delayed.

Roche to take over Genentech for $47 billion

Mar 12, 2009

(AP) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
1 / 5 (1) May 27, 2010
What a drag for Novartis!!! Not only do they lose billions in profits, but they have that much less capital to live up to the double-digit quarterly dividend that their shareholders demand.
This kind of failure is inevitable for as long as BigPharma relies on the "Profit Foremost" model of drug development. Currently, if a drug candidate shows any promise(as in, can we rush this to market?), then it will be fast-tracked in preference to another that may show greater effectiveness, but may take longer to develop, refine, and trial.
If it's all about cashflow and marketing, then the quality of the product is going to suffer, and so I laugh every time I see them step on their own dick like this. Just imagine if you or I indulged in this sort of planning. It would be just as wise to use a casino visit to determine your budget.